Janssen-Cilag

What Janssen-Cilag does

Janssen-Cilag Kft. is the Hungarian operating entity of Johnson & Johnson's pharmaceutical division (Janssen Pharmaceutical Companies), headquartered at Nagyenyed u. 8-14 in Budapest, Hungary. The entity markets and distributes Johnson & Johnson's prescription pharmaceutical portfolio across five therapeutic areas in Hungary: oncology, hematology, immunology, gastroenterology, and psychiatry. It serves Hungarian healthcare professionals primarily through the J&J Medical Cloud digital portal (jnjmedicalcloud.hu), providing medical education, product information, professional resources, and a direct contact channel for HCP engagement.

Core marketed products include TREMFYA (guselkumab), an IL-23 inhibitor approved for Crohn's disease and ulcerative colitis; RYBREVANT (amivantamab), a bispecific antibody targeting EGFR and MET in non-small cell lung cancer and head/neck cancer; CARVYKTI (ciltacabtagene autoleucel), a CAR-T cell therapy for multiple myeloma developed with Legend Biotech; Simponi (golimumab), a TNF-alpha inhibitor with $1.2 billion in U.S. sales in 2025; and DARZALEX SC, a subcutaneous formulation of daratumumab using Halozyme's ENHANZE drug delivery technology. The portfolio is supported by recent FDA approvals including subcutaneous RYBREVANT (2024), TREMFYA Crohn's disease indications, and ZUSDURI (2025). Pipeline assets advancing in clinical trials include icotrokinra (oral IL-23 peptide for psoriasis, Phase 3 ICONIC-TOTAL), nipocalimab (Sjögren's disease, Phase 2 DAHLIAS), and pasritamig combinations for metastatic castration-resistant prostate cancer.

The business operates on a prescription pharmaceutical model with revenue generated through traditional distribution channels — wholesalers, pharmacies, and hospitals — under negotiated pricing with healthcare systems, insurers, and government reimbursement programs. The Hungarian entity employs 101-250 staff and operates as a wholly-owned subsidiary of publicly traded Johnson & Johnson (NYSE: JNJ), benefiting from parent-level R&D investment including the $1.6 billion CARVYKTI manufacturing capacity at Raritan, New Jersey, while running a focused country-level commercial operation. Revenue and pricing data specific to the Hungarian entity are not publicly disclosed.

Name

Janssen-Cilag

Legal name

Janssen-Cilag Kft.

Website

https://jnjmedicalcloud.hu

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

101–250 employees

Short description

Janssen-Cilag Kft. is the Hungarian operating subsidiary of Johnson & Johnson's pharmaceutical division, marketing prescription therapies across oncology, hematology, immunology, gastroenterology, and psychiatry to Hungarian healthcare professionals via the J&J Medical Cloud platform.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Oncology Specialty Pharmaceuticals (HLAIACAA), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Prescription pharmaceuticals
• Oncology therapeutics
• Immunology treatments
• Multiple myeloma therapy
• Inflammatory disease drugs

Headquarters

HQ city

Budapest

HQ country

Hungary

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Distribution channels1 record

Marketing channels3 records

Core offering

Janssen-Cilag Kft. develops, markets, and distributes Johnson & Johnson prescription pharmaceutical products in Hungary across five therapeutic areas: oncology (RYBREVANT for lung/head and neck cancer), hematology (CARVYKTI for multiple myeloma), immunology (TREMFYA IL-23 inhibitor, Simponi TNF-alpha inhibitor), gastroenterology (TREMFYA for Crohn's disease and ulcerative colitis) and psychiatry. The company sells medicines through traditional pharmacy, hospital, and wholesale channels and supports prescribers via a dedicated healthcare-professional digital platform (J&J Medical Cloud).

Product overview

Janssen-Cilag, the pharmaceutical subsidiary of Johnson & Johnson, operates as a diversified pharmaceutical company offering products across five core therapeutic areas: Oncology (including RYBREVANT for lung and head/neck cancer), Hematology (CARVYKTI for multiple myeloma), Immunology (TREMFYA for IL-23 inhibition, Simponi for TNF-alpha inhibition), Gastroenterology (TREMFYA for Crohn's disease and ulcerative colitis), and Psychiatry. The portfolio includes both marketed products and pipeline candidates, with key brands like TREMFYA®, RYBREVANT®, CARVYKTI, DARZALEX SC, and Simponi® spanning cancer treatment, inflammatory diseases, and autoimmune disorders. Janssen-Cilag serves healthcare professionals through regional portals like J&J Medical Cloud for Hungary, providing medical education, product information, and professional services.

Differentiator

Problem solved

Functional benefit

Brands

• Janssen Medical Cloud: Digital platform for healthcare professionals providing medical information, resources, and materials ordering
• Janssen Akadémia
• J&J Medical Cloud

Products and services

• TREMFYA (guselkumab) The first fully subcutaneous IL-23 inhibitor, indicated for Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, and related chronic inflammatory conditions, prescribed by gastroenterologists, dermatologists, and rheumatologists.
• RYBREVANT (amivantamab) Bispecific antibody targeting EGFR and MET receptors, indicated for EGFR-mutated NSCLC combinations and recurrent/metastatic head and neck cancer, for prescribing oncologists.
• CARVYKTI (ciltacabtagene autoleucel) Autologous CAR-T cell therapy for relapsed/refractory and second-line multiple myeloma, manufactured through a co-development partnership with Legend Biotech, administered at certified treatment centers.
• Simponi (golimumab) TNF-alpha inhibitor for inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis, prescribed by rheumatologists and gastroenterologists.
• DARZALEX SC (daratumumab) Subcutaneous formulation of daratumumab for multiple myeloma using Halozyme ENHANZE drug delivery technology, shortening administration time versus intravenous daratumumab.
• Pasritamig Investigational antibody being evaluated in combination therapy for metastatic castration-resistant prostate cancer, currently in Phase 1b/2 clinical development.

Quantifiable outcome

• Subcutaneous RYBREVANT demonstrated 45% overall response rate with 7.2 months median duration of response in recurrent or metastatic head and neck cancer
• +4 more outcomes

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Halozyme TherapeuticscoreTechnology or Integration · 11 May 2026ENHANZE drug delivery technology partnership where Janssen's DARZALEX SC (subcutaneous formulation) drives royalty revenue growth. Halozyme reported 42% year-over-year revenue increase in Q1 2026 primarily driven by royalty revenue from ENHANZE partner products including DARZALEX SC by Janssen.
• Legend BiotechcoreStrategic or Co-development Partner · 9 May 2026Partnership for CARVYKTI (ciltacabtagene autoleucel) CAR-T cell therapy for multiple myeloma. Janssen and Legend Biotech agreed to increase CARVYKTI manufacturing capacity at Janssen's Raritan, New Jersey facility. CARVYKTI achieved record net trade sales of $334 million in Q4 2024 with 110% year-over-year growth, driven by CARTITUDE-4 label expansion to second-line multiple myeloma.
• Evotec SEcoreStrategic or Co-development Partner · 18 April 2026Evotec partners with Janssen as one of multiple major pharmaceutical firms (alongside Bristol Myers Squibb, Sanofi, Bayer, and Eli Lilly) through its drug discovery partnership model combining EVT Execute (fee-for-service contract research) and EVT Innovate (co-developed proprietary projects). Leverages AI-driven platforms and high-throughput screening for multi-year alliances.
• QuPharm AllianceminorStrategic or Co-development Partner · 13 April 2026Janssen joined the QuPharm alliance of seventeen pharmaceutical companies formed in 2020 to explore quantum computing applications in life sciences drug discovery, alongside Biogen, Boehringer Ingelheim, Roche, Pfizer, and Merck.
• GI InnovationminorStrategic or Co-development Partner · 20 March 2026GI Innovation submitted clinical trial applications in Korea and U.S. for combination therapy of GI-102 and Janssen's drug pasritamig for metastatic castration-resistant prostate cancer. Phase 1b/2 study aims to evaluate safety, tolerability, and antitumor activity, enrolling up to 107 patients over approximately three years.
• AI Drug Discovery Technology FirmscoreTechnology or Integration · 6 March 2026Janssen participates in AI-driven drug discovery with notable developments including Phase 1 clinical trials for AI-designed drug candidates in oncology and neurodegenerative disease research. Key player in AI Drug Discovery Platform market projected to reach $15,000 million by 2033.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Bayer Hungary: Hungarian affiliate of Bayer covering pharmaceuticals, consumer health, and crop science. Comparable as a diversified pharma subsidiary operating in a similar regulatory and reimbursement environment in Hungary.
• MSD Hungary (Merck): Hungarian subsidiary of Merck & Co., with leading positions in oncology (Keytruda), vaccines, and specialty pharma. Directly comparable as a top-tier pharma affiliate operating in oncology and specialty care on the same country footprint.
• Novartis Hungary: Hungarian subsidiary of Novartis covering oncology (including CAR-T Kymriah), immunology, and ophthalmology. Closely comparable in therapeutic focus, regulatory engagement model, and sales scale to Janssen-Cilag's Hungarian entity.
• AstraZeneca Hungary: Hungarian affiliate of AstraZeneca with strong oncology and biologics focus. Comparable as a specialty oncology/CV/biologics subsidiary facing similar pipeline-extension dynamics and biosimilar risk profiles in the Hungarian market.
• Pfizer Hungary: Hungarian affiliate of Pfizer, the world's largest pharma company by revenue. Directly comparable as a domestic marketing/medical-affairs subsidiary distributing branded specialty pharmaceuticals across oncology, immunology, and other therapeutic areas through a similar healthcare-professional engagement model.
• GSK Hungary: Hungarian subsidiary of GSK covering vaccines, specialty pharmaceuticals, and HIV. Comparable as a branded pharma affiliate with parallel regulatory/medical-affairs operating model in Hungary.
• Eli Lilly Hungary: Hungarian subsidiary of Eli Lilly covering diabetes, oncology, immunology (Taltz), and neuroscience. Directly comparable in therapeutic mix, branded specialty pharma positioning, and medical-affairs-driven HCP engagement.
• AbbVie Hungary: Hungarian affiliate of AbbVie with strong immunology (Humira/Skyrizi/Rinvoq) and oncology (hematology) franchises. Comparable as a specialty pharma subsidiary facing similar biosimilar-defense and indication-expansion dynamics to Janssen-Cilag.
• Sanofi Hungary: Hungarian subsidiary of Sanofi with presence in immunology (Dupixent), vaccines, and rare diseases. Comparable as a branded specialty pharma affiliate with similar Medical Affairs/medical education infrastructure targeting Hungarian healthcare professionals.
• Roche Hungary: Hungarian affiliate of Roche operating across oncology, immunology, and diagnostics. Comparable as a specialty biopharma subsidiary with strong hospital-channel engagement and biologic-heavy portfolio dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Janssen-Cilag